Google’s parent company invests $300m in biotech
Google’s parent company Alphabet has invested $300 million in a new fund that will buy stakes in European biotech companies.
Alphabet’s division Verily Life Sciences will be one of the main investors managed by Medicxi, a venture capital group.
The fund will focus on biotech companies that need financial resources to pay for clinical trials of experimental drugs.
Medicxi said in a press release on Thursday, June 15: “With this new late-stage fund, Medicxi will help fill a clear gap in Europe, where talented life sciences entrepreneurs do not have access to as much local financial support as their US-based counterparts to expand exciting opportunities into more mature companies.”
Novartis will also be a strategic investor, and together with Verily, it will appoint two members to the fund’s scientific advisory board.
Today’s stories:
Section 101 raises fundamental question: 3M
Panellists tackle patent concerns after Brexit
FBI agent and lawyers provide trade secret tips
Industry at a crossroads over section 101
Pfizer and Takeda help to tackle Africa cancer crisis
Academic patents gave $1.3tn to US output
David Cameron talks Brexit, Trump and genomes
Hospira sued for infringing allergic injection patent
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
